683 Capital Management’s Orion Biotech Opportunities Corp. Class A Ordinary Share ORIA Stock Holding History

683 Capital Management’s Portfolio ORIA Stock Details ORIA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-699,000	Closed	-$7.15M	–	306
2023 Q1	$7.15M	Sell	699,000 -500,000	-42%	-$5.08M	0.53%	58
2022 Q4	$12M	Hold	1,199,000	–	–	1.02%	31
2022 Q3	$11.8M	Hold	1,199,000	–	–	0.91%	38
2022 Q2	$11.7M	Hold	1,199,000	–	–	0.82%	41
2022 Q1	$11.7M	Hold	1,199,000	–	–	0.63%	43
2021 Q4	$11.6M	Hold	1,199,000	–	–	0.43%	51
2021 Q3	$11.8M	Buy	+1,199,000	New	+$11.7M	0.46%	54

683 Capital Management's ORIA Position: Q2 2023 in Review

683 Capital Management sold out of Orion Biotech Opportunities Corp. Class A Ordinary Share (ORIA) in Q2 2023, closing a stake of 699,000 shares — an estimated $7.15M sold.

683 Capital Management first reported a position in ORIA in Q3 2021 and held it in 7 quarters. The position peaked at $12M in Q4 2022. 0 funds tracked by Wall St. Rank hold ORIA as of Q2 2023.

683 Capital Management reported no remaining Orion Biotech Opportunities Corp. Class A Ordinary Share position as of Q2 2023 after selling out during the quarter.
683 Capital Management sold 699,000 Orion Biotech Opportunities Corp. Class A Ordinary Share shares in Q2 2023, an estimated $7.15M.
683 Capital Management first reported a position in Orion Biotech Opportunities Corp. Class A Ordinary Share in Q3 2021 and held it in 7 quarters.
683 Capital Management's Orion Biotech Opportunities Corp. Class A Ordinary Share position peaked at $12M in Q4 2022.
0 funds tracked by Wall St. Rank held Orion Biotech Opportunities Corp. Class A Ordinary Share as of Q2 2023.

Based on 683 Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.